Astrazeneca Plc (AZN) Shareholder Crawford Investment Counsel INC Increased Stake by $3.87 Million as Shares Rose

AstraZeneca PLC (NYSE:AZN) Corporate Logo

The stake In Astrazeneca Plc (AZN) was upped owned by Crawford Investment Counsel Inc. According to 2018Q2 SEC filling the reduction is 6.84%. The company’s stock popped up 4.73% while Crawford Investment Counsel Inc bought 110,487 shares. The major pharmaceuticals company reported $60.62 million value for the 2018Q2. Now the institutional investor is holding 1.73M shares, compared to the 1.62 million from the previous quarter. $100.33 billion is Astrazeneca Plc’s market cap. AZN is reaching $40.97 during the last trading session, after increased 0.79%.AstraZeneca PLC has 5.14M shares volume, 22.44% up from normal. AZN is uptrending and has moved 13.38% since November 10, 2017. AZN underperformed by 2.24% the S&P 500.

About $4.53 billion and $3.15B US Long portfolio Crawford Investment Counsel Inc operates. Its stake in Blackrock Inc (NYSE:BLK) was reduced by 6,883 shares to 117,562 shares valued at $58.67 million in 2018Q2, according to the filing. Crawford Investment Counsel Inc has cut its stake in Exxon Mobil Corp (NYSE:XOM) and also reduced its holding in Broadridge Finl Solutions In (NYSE:BR) by 488,231 shares in the quarter, for a total of 56,696 shares.

A couple more AstraZeneca PLC (NYSE:AZN) news were announced by: which released on October 23, 2018 “AstraZeneca to acquire 9.8% of Innate Pharma”, also on November 09, 2018 announced “Britain’s cost watchdog for NHS not on board with AstraZeneca’s Lynparza”, the next is “European advisory group backs six new meds” on October 19, 2018. has article titled “AstraZeneca Q3 revenues down 14%”.

AstraZeneca PLC (NYSE:AZN) Ratings Coverage

In total 2 analysts cover AstraZeneca (NYSE:AZN). “Buy” rating has 0, “Sell” are 0, while 2 are “Hold”. 0 are bullish. 2 are the (NYSE:AZN)’s analyst reports since June 12, 2018 according to StockzIntelligence Inc. On Tuesday, June 12 the stock of AstraZeneca PLC (NYSE:AZN) has “Hold” rating given by Morningstar. On Thursday, August 16 the firm has “Hold” rating by Jefferies given.

AstraZeneca PLC (NYSE:AZN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.